Pacer Advisors Inc. lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 0.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,040,742 shares of the biopharmaceutical company’s stock after selling 8,330 shares during the quarter. Bristol-Myers Squibb comprises about 1.0% of Pacer Advisors Inc.’s investment portfolio, making the stock its 23rd largest position. Pacer Advisors Inc. owned approximately 0.19% of Bristol-Myers Squibb worth $258,405,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Security Asset Management lifted its stake in shares of Bristol-Myers Squibb by 20.3% during the first quarter. Security Asset Management now owns 9,230 shares of the biopharmaceutical company’s stock valued at $640,000 after acquiring an additional 1,558 shares during the period. Richard P Slaughter Associates Inc lifted its stake in Bristol-Myers Squibb by 3.5% in the second quarter. Richard P Slaughter Associates Inc now owns 22,040 shares of the biopharmaceutical company’s stock valued at $1,409,000 after buying an additional 750 shares during the period. Talbot Financial LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $4,482,000. Ethic Inc. lifted its stake in Bristol-Myers Squibb by 26.4% in the first quarter. Ethic Inc. now owns 121,524 shares of the biopharmaceutical company’s stock valued at $8,423,000 after buying an additional 25,385 shares during the period. Finally, Atlas Wealth LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $276,000. Institutional investors and hedge funds own 74.98% of the company’s stock.
In other news, EVP Robert M. Plenge sold 732 shares of Bristol-Myers Squibb stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total value of $44,754.48. Following the transaction, the executive vice president now owns 6,584 shares in the company, valued at approximately $402,545.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the sale, the executive vice president now owns 27,868 shares in the company, valued at approximately $1,706,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert M. Plenge sold 732 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total value of $44,754.48. Following the sale, the executive vice president now owns 6,584 shares in the company, valued at approximately $402,545.76. The disclosure for this sale can be found here. Corporate insiders own 0.08% of the company’s stock.
Wall Street Analyst Weigh In
Bristol-Myers Squibb Price Performance
NYSE BMY traded down $0.20 during midday trading on Tuesday, hitting $58.38. The company had a trading volume of 2,506,812 shares, compared to its average volume of 8,964,190. The company has a market capitalization of $121.96 billion, a PE ratio of 15.58, a P/E/G ratio of 1.57 and a beta of 0.42. The company has a current ratio of 1.39, a quick ratio of 1.28 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $61.62 and a 200-day moving average price of $65.11. Bristol-Myers Squibb has a twelve month low of $58.33 and a twelve month high of $81.43.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing the consensus estimate of $1.99 by ($0.24). The company had revenue of $11.23 billion during the quarter, compared to analyst estimates of $11.81 billion. Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. Bristol-Myers Squibb’s revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.93 earnings per share. As a group, analysts anticipate that Bristol-Myers Squibb will post 7.44 earnings per share for the current fiscal year.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
- Five stocks we like better than Bristol-Myers Squibb
- How to Invest in Apparel Stocks
- Virtual Riches: 3 Stocks Leading the VR Revolution
- What is a Special Dividend?
- 5 eCommerce Companies that need to be on Your Watch List
- What is a Bond Market Holiday? How to Invest and Trade
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.